Compare CNXN & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNXN | ANIP |
|---|---|---|
| Founded | 1982 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 1997 | 1999 |
| Metric | CNXN | ANIP |
|---|---|---|
| Price | $88.21 | $77.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | 98.9K | ★ 353.5K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | 1.99 | ★ 2.32 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | $6.24 | $21.01 |
| Revenue Next Year | $4.39 | $17.59 |
| P/E Ratio | $43.17 | ★ $33.99 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $54.97 | $69.58 |
| 52 Week High | $88.35 | $96.99 |
| Indicator | CNXN | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 63.85 | 58.79 |
| Support Level | $56.09 | $75.94 |
| Resistance Level | $88.31 | $78.20 |
| Average True Range (ATR) | 2.22 | 1.97 |
| MACD | 0.30 | 1.00 |
| Stochastic Oscillator | 79.74 | 80.25 |
PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.